BIO 10901

Drug Profile

BIO 10901

Alternative Names: BIO-10901

Latest Information Update: 22 Feb 2016

Price : $50

At a glance

  • Originator North Carolina State University
  • Developer BioMarck Pharmaceuticals
  • Class Amino acids; Peptides
  • Mechanism of Action Myristoylated alanine rich C kinase substrate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome

Most Recent Events

  • 22 Feb 2016 Preclinical trials in Adult respiratory distress syndrome in USA (Inhalation) prior to February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top